Alto Neuroscience prices $93.9 million stock offering to fund ALTO-207 trial
Alto Neuroscience entered into an underwriting agreement on July 13, 2026, to sell 3,776,436 shares of common stock at $26.48 per share in a registered direct offering, with estimated net proceeds of approximately $93.9 million. The company plans to use the proceeds with its existing cash to accelerate ALTO-207 development, including an additional planned Phase 3 trial in treatment-resistant depression. The sale adds new shares outstanding, which dilutes existing holders, and closing is expected July 14, 2026.
Key points
- Shares offered: 3,776,436 common shares at $26.48 each
- Estimated net proceeds: approximately $93.9 million, after underwriting discounts and offering expenses
- Use of proceeds: ALTO-207 clinical development, including an additional Phase 3 trial in treatment-resistant depression, and general working capital
- Expected closing: July 14, 2026, subject to customary conditions; BofA Securities is representative
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.